TIDMEVG

RNS Number : 5933P

Evgen Pharma PLC

30 May 2018

 
 For immediate release   30 May 2018

Evgen Pharma plc

("Evgen" or "the Company")

Notification of Preliminary Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2018 on Wednesday 13 June 2018.

A meeting for analysts will be held at 10.30am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further information, or to register attendance, please contact Buchanan at the contact details below.

Enquiries:

 
 Evgen Pharma plc                       c/o +44 (0) 20 7466 
  Dr Stephen Franklin, CEO                             5000 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Wills, Tilly           +44 (0) 20 7466 
  Abraham                                              5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Tom Price, Gerry 
  Beaney (Corporate Finance) 
  John Howes, Rob Rees (Corporate           +44 (0) 20 3861 
  Broking)                                             6625

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORUKSNRWOAVUAR

(END) Dow Jones Newswires

May 30, 2018 02:01 ET (06:01 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma